Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERAS-801 in Recurrent or Elderly Newly Diagnosed Glioblastoma
NCT07089641Phase 1Recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ERAS-801 in glioblastoma (GBM) and Gliosarcoma (GS) (3 cohorts), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Fludeoxyglucose F-18 (FDG) tumor uptake, Pharmacokinetics (PK) dose modification at day 15 and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
ERAS-801
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT07089641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07089641.